NasdaqGS - Nasdaq Real Time Price USD

Bio-Techne Corporation (TECH)

Compare
72.65 +0.31 (+0.43%)
At close: August 21 at 4:00 PM EDT
73.40 +0.75 (+1.03%)
After hours: August 21 at 6:50 PM EDT
Loading Chart for TECH
DELL
  • Previous Close 72.34
  • Open 72.96
  • Bid 72.57 x 300
  • Ask 72.71 x 600
  • Day's Range 71.90 - 73.22
  • 52 Week Range 51.79 - 85.57
  • Volume 903,264
  • Avg. Volume 1,011,182
  • Market Cap (intraday) 11.449B
  • Beta (5Y Monthly) 1.29
  • PE Ratio (TTM) 69.19
  • EPS (TTM) 1.05
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield 0.32 (0.44%)
  • Ex-Dividend Date Aug 19, 2024
  • 1y Target Est 82.78

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

www.bio-techne.com

3,100

Full Time Employees

June 30

Fiscal Year Ends

Recent News: TECH

View More

Research Reports: TECH

View More

Performance Overview: TECH

Trailing total returns as of 8/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TECH
5.54%
S&P 500
17.84%

1-Year Return

TECH
6.71%
S&P 500
28.63%

3-Year Return

TECH
38.67%
S&P 500
26.55%

5-Year Return

TECH
54.06%
S&P 500
93.79%

Compare To: TECH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TECH

View More

Valuation Measures

Annual
As of 8/21/2024
  • Market Cap

    11.45B

  • Enterprise Value

    11.72B

  • Trailing P/E

    69.19

  • Forward P/E

    38.31

  • PEG Ratio (5yr expected)

    1.82

  • Price/Sales (ttm)

    10.08

  • Price/Book (mrq)

    5.53

  • Enterprise Value/Revenue

    10.11

  • Enterprise Value/EBITDA

    36.79

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.50%

  • Return on Assets (ttm)

    4.85%

  • Return on Equity (ttm)

    8.33%

  • Revenue (ttm)

    1.16B

  • Net Income Avi to Common (ttm)

    168.1M

  • Diluted EPS (ttm)

    1.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    152.86M

  • Total Debt/Equity (mrq)

    20.28%

  • Levered Free Cash Flow (ttm)

    190.52M

Research Analysis: TECH

View More

Company Insights: TECH

People Also Watch